Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence
Status unconfirmed · Phase 1
Conditions studied: Opiate Dependence
In brief
Opiate dependence is a serious problem, and oxytocin has many properties which make it attractive as a treatment for this type of substance dependence. This experiment will test the effects of oxytocin on a variety of brain-based processes in patients with opiate dependence. The investigators hypothesize that intranasal oxytocin in these conditions will enhance emotional processing and will have beneficial effects on stress responses in opiate-dependent patients.
Key facts
- Study ID
- NCT02052258
- Run by
- MacDonald, Kai, M.D.
- Starts
- 2013-01-01
- Last updated by the study team
- 2014-09-15
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- adult men 18 years or older
- meet DSM-IV criteria for opiate dependence, and no other active substance dependence disorder save nicotine dependence
- clinically stable, and low risk for suicide as determined by principal investigator and screening questionnaire
- abstinent from non-prescribed opiate use for at least two weeks from Baseline 1 and free from opiate withdrawal symptoms. If on agonist therapy, dose must be stable for 2 weeks before study visit.
- must be able to use nasal spray
- negative salivary drug screen, save for opiates
You may not qualify if…
- any active medical condition that in the opinion of the investigator will interfere with the objectives of the study
- any active, severe mental illness, neurological disorder, including schizophrenia, autism, Asperger's syndrome
- are unsuitable in any way to participate in this study, in the opinion of the investigator
- hospitalizations due to complications of an Axis 1 disorder for the past 12 months, excluding drug or alcohol rehabilitation
- any clinically significant chronic pain condition, as determined by the principal investigator
- positive salivary drug screen at the time of the visit, for any substance other than opiates or another prescribed medication
Where it is running
- UCSD Medical Center — San Diego, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.